Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.
Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.
In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.
Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.
Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.
Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.
“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."
Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.
For the past several decades, much of the work to find a treatment for AD has been focused on eliminating those dreaded Aβ plaques, by assuming that memory could be restored by removing the plaques.
KYNETIC, funded by the National Institutes of Health (NIH), is excited to announce that five of the seven projects recently awarded $50,000 to bring their innovations toward product development are from the University of Kentucky.
